Events / Education

Venue: Palais de L’Europe, 8 Avenue Boyer, 06506 Menton, France

Date:  Sunday 7^th to Tuesday 9th October 2018

Keynote lectures:

Big data initiatives changing the future of cancer imaging and therapy

PSMA molecular imaging and theranostics

Cancer imaging: through a looking glass

Main sessions:

Myeloma

Lymphoma and myelofibrosis

Imaging musculoskeletal cancer

Imaging immunotherapy

Clinical needs in pancreatic tumours

Liver tumours I

Lung cancer

Federation du cancer from the French Society of Radiology

Multiparametric imaging

Liver tumours II

Break-out sessions:

Abdominal oncology

Interventional radiology

Neurooncology

Imaging complications of cancer therapy

Haematologic cancer

Cases I would like to read again

Computer hands-on workshops:

Lung cancer staging

Pancreatic lesions

Whole body MRI

Prostate cancer

Gynaecological cancer

HCC diagnostic using LIRADS with CT, MRI or CEUS?

Scientific paper sessions and poster exhibition

Prizes for the best oral presentations and best posters will be awarded at the course party on Monday evening.

Other info:

Course party at the Casino, Menton. Monday 8th October 19.30 €50 for delegates and Fellows' partners & guests (unlimited number of tickets can be purchased).  1 Complimentary ticket for Fellows.

Fellows' AGM on Saturday 6th October 16.30 to 17.30

Fellows' dinner at Maison Martin et Fils, 7 Rue de Marins, Menton. Saturday 6th October 19.00. Complimentary limited to two tickets per fellow. 

Accommodation

Delegates are responsible for making their own arrangements for accommodation and should book via the given web link. We strongly recommend you book early to secure the best rates.

The top 10 rated hotels in Menton (starting from £42 per night at time of writing)  - https://www.tripadvisor.co.uk/Hotels-g187231-Menton_French_Riviera_Cote_d_Azur_Provence_Alpes_Cote_d_Azur-Hotels.html

Getting to Menton

Travel

By Air

Nice Côte d'Azur is the closest international airport, 35km away or a 45 minute drive.

By Taxi

You can prebook a taxi (from €70 per car), or share the journey and get a larger 8 seater minibus (from as little as €90 per van) by clicking here. 

By Train

To travel to Menton Station from Nice Airport please take a taxi to Nice Rail Station, and then a direct train from €5.50 one way.  You may book these tickets here 12 weeks before the date of travel. 

https://www.trainline.eu

If you are travelling by train from a different part of France, click here to see an interactive map of the French Railway network. 

https://www.sncf-reseau.fr/en

By Bus

It is possible to travel to Menton by bus, however we do not recommend this as the train is excellent value and much quicker.  If you would prefer to take the public bus, please board bus number 110 from Nice Airport.  Not all of these are direct and so you may have to change at Monaco.

You will be able to generate your own certificate of attendance once you have completed our daily online feedback form.

The Royal College of Radiologists (Category 1 (external) CPD credits)
Sunday 7 October - 6.5 credits
Monday 8 October - 6.5 credits
Tuesday 9 October - 4 credits

European Accreditation Council for CME (EACCME)
(European CME credits (ECMEC))  have been applied for

American delegates can have their EACCME European CME Credits converted to AMA PRA Category 1 Credit™ by applying to the AMA.

Download the 1 page from here:- https://www.ama-assn.org/sites/default/files/media-browser/public/cme/eaccme-application.pdf

Send the completed  form to the AMA together with the EACCME certificate* and the non-refundable processing fee (AMA members $30 and non AMA members $75).  AMA certificates will be emailed within 3 business weeks. 

* The EACCME certificate will be automatically emailed to you once you have completed the ICIS course daily electronic surveys.

Please visit this link for further information https://www.ama-assn.org/education/uemseaccme-cme-credit-recognition

» Guidelines   » Examples  » Download Abstract Guidelines  

General Rules

Abstracts that do not adhere to the following important points will be rejected:

> The title should not exceed 15 words.  The title should be in bold, sentence case with no full stop at the end and no underlining.
> The abstract should not exceed 250 words.
> Please use authors’ initials and surnames only. No full stop at the end. Underline the name of the corresponding author. A comma should separate author names. Where authors are from a number of different institutions, the appropriate institution number from the affiliation list should be given as a superscript number immediately after each author's name, e.g.: John Smith1, Susan Jones1, Bill Fisher2. An asterisk * should be used to link the corresponding author with their email address
> Affiliations should include institute, town and country. Where there are multiple affiliations, each should be listed as a separate paragraph. Each institute should appear in the order used against the author names (see above paragraph) and show the appropriate superscript number, e.g.:

           1 University, Town, State, USA
           2 University, Town, UK
           2 Company, Town, Country

> Qualifications should be omitted.  
> Do not include references, tables or figures.
> Please do not use block capitals.

Main text

> In structured abstracts, paragraph headings should be typed in bold with no colon at the end. Do not use the heading ‘Abstract’. Each heading should be in a separate paragraph.

Aim

Followed by regular text, on a new line and in the same format as shown above for main text.

Materials & Methods

Results

Conclusions

Consent to publish If the abstract contains details relating to individual participants (for example a case report), written informed consent for the publication of these details must be obtained from the participants and a statement to this effect should appear at the end of the abstract. Our guidelines for consent statements can be found here: http://www.biomedcentral.com/about/editorialpolicies#Ethics. If the patient is deceased consent for publication should be obtained from the next of kin and if the patient is under 16 consent should be obtained from the parent or guardian.

Please find examples at the bottom of the page.

Guidelines

You may choose among four different abstract types:
> Oral Scientific Presentation
> Oral Case Based Presentation
> Poster Scientific Presentation
> Poster Educational Presentation

Oral Scientific Presentation
The abstract should be separated into “Aim”, “Methods”, “Results” and “Conclusion”. The abstract limit is 250 words.  Abstracts should not include promissory notes such as “We will provide additional data during our presentation.”  Authors of accepted oral presentations will be invited for a presentation within the Scientific Paper Sessions.  Presentation time will be 8 minutes with 2 minutes for Q&A (depending on the final program). 

Oral Case Based Presentation
The abstract should have an image and three teaching points. The abstract limit is 250 words.  Abstracts should not include promissory notes such as “We will provide additional data during our presentation.”  Authors of accepted oral case based presentations will be invited for a presentation within the Scientific Paper Sessions.  Presentation time will be 8 minutes with 2 minutes for Q&A (depending on the final program). 

Poster Scientific Presentation
The abstract should be separated into “Aim”, “Methods”, “Results” and “Conclusion”. The abstract limit is 250 words. 

Poster Educational Presentation
The abstract should be separated into “Learning Objectives”, “Content Organisation”,  and  “Conclusion”. The abstract limit is 250 words. 

Proceedings of the 18th International Cancer Imaging

Abstracts selected for presentation will be published in the Proceedings of the 18th International Cancer Imaging, given to all delegates and faculty. A downloadable version of your submission will be made available to our membership on the members only area of our website, and be available on the Cancer Imaging open access website. Authors of selected abstracts will be notified after Friday 6th July 2018.

It will be obligatory for all scientific presenters to be members of ICIS at the time of presentation in Menton. The annual membership fee of €95 will be added to the scientific presenters’ fee at registration if current membership is not in place. Please note that we have a discounted trainee membership at €39 and a much reduced trainee registration fee for the course.  Membership will run for one year from date of registration; all standard member benefits will apply.

Financial help will be available for junior proffered presenters.  This will be decided on application and on a case-by-case basis.  Kindly supported by the French Society of Radiology.  

Applicants for financial aid please email [email protected] for further information.

Queries may be addressed to the ICIS Secretariat

Tel: +44 (0) 7956 814964 or Email: [email protected]

Submission deadline: Monday 4th June 2018

Examples

EXAMPLE – ORAL CASE BASED PRESENTATION

Diagnosis: Advanced Cervix Cancer

Sala E.

Memorial Sloan Kettering Cancer Center, New York, USA

Images:

Teaching/Discussion points:

> Discuss the role of MRI in treatment slection and planning of patients with cervical cancer
> Describe MRI Features of parametrial and pelvic sidewall invasion
> Highlight potential pitfalls

EXAMPLE - POSTER EDUCATIONAL

Chemotherapy induced cardiomyopathy: an overview, imaging features, and future prospective

Firstname A Lastname1*, Firstname B Lastname2, Firstname C Lastname3

1University, Town, State, USA
2University, Town, UK
3Company, Town, Canada

*Email address of corresponding author if being included

Learning objectives:

To review the spectrum of imaging findings of chemotherapy- induced cardiomyopathy in correlation with most common cytotoxic drugs and regimens. 

Content organisation:

Cardio toxic effect of chemotherapy is a well-recognized problem in cancer patients.  Cardio toxicity depends on multiple predisposing factors, specific components of the chemotherapy regimen, length of treatment, and dosage.

We will present the spectrum of most common cardiotoxic chemotherapy agents and their combinations, specific effects on the myocardium, and imaging features of cardiomyopathies induced by chemotherapy.

We will review pathophysiology of chemotherapy induced cardiomyopathy including:

- Dose dependent cardiomyopathy

- Predisposing conditions –diabetes, presence of coronary artery disease, age.

- Potential reversibility

We will discuss imaging characteristics of chemotherapy induced cardiomyopathy

- Imaging modalities ( Echocardiography, Cardiac MR, and MUGA)

- Importance of monitoring cardiac function during and after treatment

- Distribution of late Gadolinium enhancement (LGE)

- Emerging technologies for early diagnosis of cardiomyopathy in cancer patients

Conclusions:

Chemotherapy induced cardiomyopathy is a common problem among cancer patients, increasing long term morbidity and mortality and often leading to disability. Patients receiving chemotherapy treatment, particularly cardio toxic agents, should be routinely assessed for cardiac function to diagnose cardiomyopathy during the early phase of treatment and to prevent development of irreversible heart failure.

EXAMPLE POSTER SCIENTIFIC

The value of 68Ga-PSMA enhanced MR-PET in patients with biochemical recurrent prostate cancer

Firstname A Lastname1*, Firstname B Lastname2, Firstname C Lastname3

1University, Town, State, USA
2University, Town, UK
3Company, Town, Canada

*Email address of corresponding author if being included

Aim:  In patients with prostate Cancer increased levels of PSMA can be measured. Recently a new tracer, ⁶⁸Ga-PSMA, was developed as a specific marker for hybrid imaging (PET/CT, MR-PET). In this study we evaluated the accuracy of ⁶⁸Ga-PSMA in patients with rising PSA after radical prosatectomy, so called „biochemical recurrent prostate cancer“ (BRPC).

Materials and Methods:  A total of 322 patients with BRPC underwent a MR-PET examination (Siemens Biograph mMR) after injection of about 150 mBq ⁶⁸Ga-PSMA. Images were evaluated in cosensus by one experienced nuclear medicine physician  and one radiologist. Pelvine lymphnode dissection was performed in most of the patients according to a predefined template with 8 fields. Lymphnode involvement was evaluated according to a 5 point scale with a patient-  and a field-based analysis.  These findings were startified according to PSA-values.

Results:  Four patients were excluded from the study for different reasons. Sensitivity for detction of recurrence was 95.7 % for PSA-values ≥ 2ng/ml, 81.4 % for PSA-values of 1-2 ng/ml, 76% for PSA-values 0.5-1 ng/ml, and 51% for PSA values ≤ 0.5 ng/ml. In comparison to the MR-images alone MR-PET was of superior diagnostic value.

Conclusions:  MR-PET using ⁶⁸Ga-PSMA is a sensitive and highly accurate technique for the diagnosis of  biochemical reccurence of prostate cancer after radical prostatectomy. It yields high diagnostic performance at relatively low PCA-values.